Daymark Wealth Partners LLC Increases Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Daymark Wealth Partners LLC boosted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 1.7% in the fourth quarter, HoldingsChannel.com reports. The fund owned 41,500 shares of the biopharmaceutical company’s stock after purchasing an additional 689 shares during the period. Daymark Wealth Partners LLC’s holdings in TG Therapeutics were worth $1,249,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in TGTX. State Street Corp raised its position in shares of TG Therapeutics by 35.8% during the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after purchasing an additional 2,398,015 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of TG Therapeutics during the second quarter worth approximately $36,501,000. Principal Financial Group Inc. lifted its holdings in TG Therapeutics by 1,549.4% in the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after purchasing an additional 725,371 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in TG Therapeutics during the 2nd quarter worth $10,423,000. Finally, Public Sector Pension Investment Board acquired a new stake in TG Therapeutics during the 3rd quarter worth $6,619,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Stock Down 2.4 %

Shares of NASDAQ:TGTX opened at $29.14 on Thursday. The business has a 50-day moving average price of $31.57 and a 200 day moving average price of $26.01. TG Therapeutics, Inc. has a 12-month low of $12.84 and a 12-month high of $36.84. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The company has a market capitalization of $4.54 billion, a price-to-earnings ratio of -291.37 and a beta of 2.24.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. During the same quarter in the prior year, the company posted $0.73 earnings per share. The business’s revenue was down 49.4% compared to the same quarter last year. Sell-side analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analyst Ratings Changes

TGTX has been the topic of several research reports. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 7th. TD Cowen initiated coverage on TG Therapeutics in a report on Tuesday, October 29th. They set a “buy” rating and a $50.00 target price on the stock. The Goldman Sachs Group increased their price target on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. boosted their price objective on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a research note on Wednesday, January 15th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

Insider Activity at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the sale, the chief financial officer now directly owns 660,611 shares in the company, valued at $18,847,231.83. This represents a 1.49 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Sagar Lonial sold 5,000 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the transaction, the director now owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. This trade represents a 4.75 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,358 shares of company stock worth $781,497 in the last three months. 10.50% of the stock is owned by company insiders.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.